What happened
Jeonjinbio reported separate results for FY2025: revenue of US$9.43M (−28.94% year on year), an operating loss of US$236K (from a profit a year earlier) and a net loss of US$135K (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$9.43M |
|---|---|
| Revenue vs a year earlier | −28.94% |
| Operating profit | −US$236K |
| Net income | −US$135K |
| Period | FY2025 (separate) |
| Filed | 2026-02-03, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260203901070 → open original filing |
Source: DART. Information only, not investment advice.